A BCL-X-L PROTAC degrader DT2216 synergizes with KRAS(G12C) inhibitors for effectively treating KRAS(G12C)-mutated cancers.

CANCER RESEARCH(2022)

Cited 0|Views8
No score
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined